We studied the effect of CTLA-4 blockade on graft-versusleukemia and graft-versus-host responses in a mouse model of minor histocompatibility-mismatched bone marrow transplantation. Early CTLA-4 blockade induced acute graft-versus-host disease. Delayed CTLA-4 blockade resulted in a lethal condition with lymphosplenomegaly, but with stable mixed T-cell chimerism, unchanged alloreactive T-cell frequencies and absent anti-host reactivity in vitro. In contrast, multiorgan lymphoproliferative disease with autoimmune hepatitis and circulating anti-DNA auto-antibodies were documented. Splenic lymphocytes exhibited ex vivo spontaneous proliferation and a marked proliferative response against host-type dendritic cells pulsed with syngeneic (host-type) tissue-peptides. Both phenomena were exclusively mediated by host and not donor T cells, supporting an autoimmune pathogenesis. Selectively hostderived T-cell immune reactivity was equally documented against leukemia-peptide-pulsed dendritic cells, and this was paralleled by a strong in vivo antileukemic effect in anti-CTLA-4-treated and subsequently leukemia-challenged chimeras. In conclusion, delayed CTLA-4 blockade induced a host-derived antileukemic effect, occurring in the context of an autoimmune syndrome and strictly separated from graft-versus-host disease. Both antileukemic and autoimmune responses depended on the allogeneic component, as neither effect was seen after syngeneic bone marrow transplantation. Our findings reveal the potential of using CTLA-4 blockade to establish antileukemic effects after allogeneic hematopoietic stem cell transplantation, provided autoimmunity can be controlled.
Introduction
The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies, for example, chronic myelogenous leukemia and acute myeloid leukemia, critically depends on the immune-mediated graft-versusleukemia (GVL) effect.
1,2 GVL responses often occur in the context of broad anti-host reactivity, [3] [4] [5] [6] in close association with graftversus-host disease (GVHD). Current HSCT strategies aim at maximizing GVL effects while minimizing GVHD and treatment-related toxicity. Although tumor-specific antigens exist, [7] [8] [9] separation of the beneficial GVL effects from potentially deleterious GVHD and graft rejection has until now remained an elusive goal.
Multiple co-signaling pathways exist, forming a complex network of co-stimulating or co-inhibiting signals that regulate immune reactivity. 10 Among these, the T-cell receptors CD28 and CTLA-4 and their ligands B7.1 (CD80) and B7.2 (CD86) on antigen-presenting cells (APC) have been most extensively studied. 11 While the CD28 signal is required to sustain and enhance T-cell activation, the interaction of B7 isoforms with CTLA-4 elicits an inhibitory signal. 12 This is most dramatically apparent in CTLA-4 À/À mice, which exhibit a massive and rapidly lethal lymphoproliferative syndrome. [13] [14] [15] In vivo blockade of CTLA-4 accelerates or exacerbates autoimmune disease in murine models of experimental autoimmune encephalomyelitis and autoimmune diabetes. 16, 17 Also, CTLA-4 blockade, alone or in combination with other immunointerventions, [18] [19] [20] [21] [22] [23] can lead to rejection of transplanted tumor cell lines in mice, and this observation has recently led to phase I clinical trials with anti-human CTLA-4 monoclonal antibodies (mAb) in patients with melanoma or ovarian carcinoma. [24] [25] [26] [27] In a mouse model of major histocompatibility (MHC) mismatched bone marrow transplantation (BMT), early CTLA-4 blockade enhanced alloreactivity, resulting in either GVHD or graft rejection. Later after BMT, CTLA-4 blockade in conjunction with donor lymphocyte infusion (DLI) elicited a significant antitumor effect, but severe GVHD precluded a survival advantage. 28 In clinical practice, the selection of an eligible allogeneic donor relies on optimal histocompatibility matching, with over 50% of patients receiving an MHC-matched (sibling or unrelated) donor transplant. 29 Here, we investigated the effect of CTLA-4 blockade without DLI on GVL effects and GVHD, in the context of MHC-matched, minor histocompatibility (miHC)-mismatched BMT. We show that CTLA-4 blockade can establish an antileukemic effect in the absence of GVH reactivity. This was, however, associated with an autoimmune condition, counterbalancing a potential beneficial effect on survival.
Materials and methods

Animals
Female mice (10- 
BMT
Recipient AKR mice were conditioned with 7.5 Gy total body irradiation. On day (d) 0, recipients were reconstituted with 5 Â 10 6 non-T-cell-depleted C3H BM cells (allogeneic BMT) or AKR BM cells (syngeneic BMT). 4 
Monoclonal antibodies
Blocking hamster-anti-mouse CTLA-4 mAb (UC10-4F10) (Bioceros BV, Utrecht, The Netherlands) and polyclonal hamster IgG (Jackson ImmunoResearch, Westgrove, PA, USA) were administered i.p. The early treatment schedule consisted of 250 mg on d-1 and 0 and 100 mg on d4, 8 and 12. Delayed treatment consisted of 250 mg on d20 and 21 and 100 mg on d25, 29 and 33. Naïve mice were treated on d0 and 1 (250 mg) and d5, 9 and 13 (100 mg).
Leukemia challenge
The BW5147.3 AKR mouse lymphoma line (ATCC) was used for leukemia challenge on d28 and in naïve mice on d8 after the start of CTLA-4-blocking treatment.
Assessment of GVHD
Animals were inspected daily. They were weighed and scored for GVHD weekly. Signs of GVHD typically observed in this model are weight loss, ruffled fur, hunched posture, diarrhea and lethargy, 4, 30, 31 in accordance with other mouse models of GVHD. 32 On the basis of the published clinical GVHD scores, each parameter was scored as follows: 0 ¼ normal, 1 ¼ mild, 2 ¼ moderate and 3 ¼ severe. 33 The maximal score was 12. For histological confirmation of GVHD, liver, colon and spleen were obtained from moribund animals or from necropsies. HEstained samples were coded and read by a certified pathologist (CDW-P), and a semiquantitative scoring system (grades 0.5-4.0) was used. 34 
Immunofluorescence
Five micrometer sections from snap-frozen tissues were incubated with anti-CD16/32(FcgIII/IIR) mAb and stained with anti-Thy1.1-FITC mAb (BD Biosciences, Erembodegem, Belgium).
Flow cytometry
Peripheral blood lymphocytes (PBL) were analyzed using a FACSort (BD Biosciences). After red blood cell lysis, PBL were labeled with FITC-, PE-or PerCP-conjugated mAb against Thy1.1, Thy1.2, TCR-Vb6, TCR-Vb3, CD3, CD4 and CD8, or with the appropriate isotype mAb (Serotec, Oxford, UK; BD Biosciences; Caltag Laboratories, Synbio bv, AM Uden, The Netherlands).
Ex vivo assays
In the mixed lymphocyte reaction (MLR), responder cells (nylon wool-enriched splenocytes) and mitomycin-C-treated (Kyowa 35 and analyzed by flow cytometry 5 days later. In the dendritic cell (DC)-based proliferation assay, responder cells (nylon wool-enriched lymph node cells from chimeras) were separated in donor-and hostderived cells by Thy1.1 þ or Thy1.2 þ cell depletion, respectively. 4 DC were cultured from BM cells. 36 Peptide suspensions were prepared by sonication of salivary glands from naïve hosttype AKR mice or by sonication of BW5147.3 cells. On d8 on DC culture, DC were pulsed with 200 mg peptide per 1 Â 10 6 DC. On d10, non-adherent cells were harvested, CD11c þ cells were positively selected with Microbeads (Miltenyi Biotec, AD Utrecht, The Netherlands) and irradiated. Responder cells were cultured with these peptide-pulsed DC at a ratio of 1 Â 10 5 -5 Â 10 3 , in the presence of IL-2 (10 U/ml, Immunosource HalleZoersel, Belgium) for 5 days. 37 Cells were pulsed with [ 3 H]thymidine for the final 18 h of culture and harvested. 4 Results are expressed as c.p.m.
Other
Plasma ALT, ALP and bilirubin were measured by automated laboratory procedures (Modular P, Roche, Belgium). Plasma anti-DNA Ab were measured by ELISA using alkaline phosphatase-conjugated goat F(ab)2 anti-mouse IgG (Biosource, Camarillo, CA, USA; dilution 1/1000). 38 
Statistics
The Mann-Whitney U-test and Fisher's exact test were used to estimate the level of statistical significance of the difference between groups of data. The log-rank test was used to estimate the level of significance of the difference in survival between groups (a P-value o0.05 was considered as evidence for statistical significance).
Results
Early CTLA-4 blockade at the time of BMT induces acute GVHD Anti-CTLA-4-treated mice developed typical clinical GVHD with 60% fatality rate (P ¼ 0.00007, Figure 1a ). Single cell necrosis of the liver (Figure 2a ), crypt cell necrosis ( Figure 2b ) with lymphocytic infiltration in the intestinal lining and lymphocytic depletion of the splenic white pulp (not shown) were seen. Surviving animals had a transient course with partial recovery of body weight ( Figure 1a ). On d14, donor T-cell chimerism was significantly higher in anti-CTLA-4-treated animals (P ¼ 0.013, Figure 1b) , with an expansion of hostreactive TCR-Vb6
T-cell frequencies remained equally low in both groups (data not shown).
Delayed CTLA-4 blockade results in a lymphoproliferative wasting syndrome that is clinically and histopathologically distinct from GVHD From d30, all anti-CTLA-4-treated mice developed a wasting syndrome with alopecia, hunched posture and cachexia, resulting in 40% mortality. All control chimeras remained healthy (P ¼ 0.0028, Figure 3a ). Surviving anti-CTLA-4-treated chimeras (60%) had a transient course with resolution of symptoms and recovery of body weight. Moribund mice had marked lymphadenopathy and splenomegaly with increased total splenocyte counts (12879 Â 10 6 cells in treated (n ¼ 41) versus 8574 Â 10 6 cells in control (n ¼ 40) chimeras, P ¼ 0.000008, Mann-Whitney U-test). The peripheral CD4/ CD8 ratio was unchanged under CTLA-4 blockade (7.570.7 in treated (n ¼ 15) versus 6.970.7 in control (n ¼ 18) chimeras, 6 experiments, P ¼ 0.4, Mann-Whitney U-test). Lymphoid aggregates were seen in intestines, gastric tissue and salivary glands (Figure 2d-f) and signs of GVHD were absent. Small infiltrating lymphocytes were seen in the thyroids; the splenic white pulp was enlarged with prominent follicles, lymphocytic coronas and marginal zones; lymph nodes showed numerous activated lymphocytes; thymuses showed cortical hyperplasia (images not shown); livers showed periportal and centrolobular mononuclear cell infiltrates with plasma cells (Figure 2c ), and signs of extramedullar hematopoiesis, but no single cell necrosis typical of GVHD.
Transplantation tolerance is maintained after delayed CTLA-4 blockade On d35, donor T-cell chimerism was similar in anti-CTLA-4-treated (5074%) and control (5974%) chimeras. Frequencies of host-reactive TCR-Vb6 þ and donor-reactive TCR-Vb3
þ and CD8 þ T cells were equally low in both groups (Figure 3b ), indicating that CTLA-4 blockade did not interfere with bidirectional transplantation tolerance. In order to further prove this, MLRs were performed on splenocytes from d35 treated and control chimeras ( Figure 3c ). As expected, control chimeras failed to mount anti-host or anti-donor proliferative responses, but maintained an intact third-party response. However, splenocytes from treated chimeras showed a striking spontaneous proliferative response (P ¼ 0.015 for difference with control chimeric splenocytes, Figure 3d ). This proliferation was not increased in the presence of donor-or host-type stimulator cells, but the third-party response was maintained (Figure 3c ). These data demonstrate that delayed CTLA-4 blockade is associated with lymphoproliferation in vivo and ex vivo. That, meanwhile, bidirectional host-donor transplantation tolerance is maintained suggests that the condition derives from a breach in tolerance to self.
Evidence for an autoimmune mechanism underlying the CTLA-4-blockade-induced wasting syndrome First, in 46 of 57 treated chimeras, strongly positive titers of circulating anti-DNA were documented, in contrast to only 24 out of 52 control chimeras exhibiting mildly positive titers (P ¼ 0.0006, Figure 4a ). Plasma ALT levels were significantly higher in treated than in control chimeras (P ¼ 0.0009, Figure 4b ). In contrast, bilirubin levels were similar (0.1570.002 in treated and 0.1670.007 mg/dl in control chimeras) and ALP levels were significantly lower in treated (160721 U/l) than in control chimeras (237715 U/l, P ¼ 0.006, Mann-Whitney U-test). Predominant enhancement of ALT levels is indicative of autoimmune hepatitis, whereas the absence of elevated ALP and bilirubin levels argues against GVHD in the liver. [39] [40] [41] Furthermore, liver histopathology of anti-CTLA-4-treated chimeras revealed periportal mononuclear cell infiltrates containing plasma cells, as is typical for autoimmune interface hepatitis. 40, 42 Second, immunofluorescent staining (Figure 2g-h) confirmed that the intestinal infiltrates of treated chimeras consisted nearly exclusively of lymphocytes expressing the host-type T-cell antigen Thy1.1, consistent with a self-reactive character of the inflammatory response. þ T-cell frequency (mean7s.e., treated n ¼ 4 and control n ¼ 5 chimeras from one representative of three identical experiments), compared with naïve adult host or donor mice (AKR n ¼ 3 and C3H n ¼ 3 mice).
# Po0.05 (Mann-Whitney U-test).GVHD, graft-versushost disease.
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Third, we documented that host T cells (CD3 þ Thy1.2 À ) from treated chimeras proliferated spontaneously in vitro, whereas donor T cells (CD3 þ Thy1.2 þ ) from the same animals failed to do so (Figure 4c) .
Finally, Figure 4d shows that, in confirmation of a breach in tolerance to self, host lymph node lymphocytes from d35 treated animals responded vigorously against host DC, pulsed with host salivary gland peptides, in contrast with donor lymphocytes from the same chimeras (P ¼ 0.008). As negative controls for this experiment we certified that low proliferative responses were obtained with host and donor lymphocytes from control chimeras as responders, or with non-pulsed DC as stimulators. In (g and h) Details of a lymphoid aggregate on a frozen section of the intestine (g) and stomach (h) of a treated chimera, revealing predominant presence of Thy1.1-expressing lymphocytes.GVHD, graft-versus-host disease. the latter setting, again, spontaneous proliferation of host-derived lymphocytes from treated chimeras could be documented.
The CTLA-4 blockade-induced autoimmune condition is associated with an antileukemic effect Treated and control chimeras were challenged with BW5147.3 leukemia cells on d28. All control mice developed cachexia and hind leg paralysis with a clinically visible perianal tumor mass, typical of fatal leukemic disease in this model (Figure 5a ). 4 Histopathology confirmed the presence of diffuse leukemic infiltration (Figure 5b ). Treated chimeras, however, consistently exhibited the clinical picture of the lymphoproliferative syndrome seen in anti-CTLA-4-treated chimeras not given leukemia cells. Except for a single mouse, none of these anti-CTLA-4-treated and leukemia-challenged chimeras developed hind leg paralysis or leukemic organ infiltration (P ¼ 0.002). In contrast, these mice had typical multiorgan lymphoproliferative lesions as in previous experiments (as in Figure 2c-f) .
The DC-based proliferation assay (Figure 4d ) demonstrated that host lymphocytes from treated chimeras mounted a stronger in vitro proliferative response against tumor-specific peptides than donor lymphocytes from the same chimeras (P ¼ 0.008). Lymphocytes from control chimeras did not mount a response in this assay.
CTLA-4 blockade in naïve mice or after syngeneic BMT does not lead to autoimmunity or GVL
To determine whether the allogeneic setting plays a role in the development of autoimmunity and/or antileukemic effect, AKR host-type mice were irradiated, given a syngeneic BMT and treated with anti-CTLA-4 or control hamster IgG from d20. All treated mice survived without clinical features of autoimmunity (not shown), but with mild lymphosplenomegaly and ex vivo spontaneous proliferation (Supplementary Figure 1a) . Delayed CTLA-4 blockade in syngeneically transplanted mice, challenged with leukemia on d28, failed to establish an antileukemic effect (Supplementary Figure 1b) . Naïve adult AKR host-type mice, treated with the same CTLA-4-blocking regimen remained completely healthy without developing lymphosplenomegaly (not shown). Splenocytes of these animals did not Figure 1c) , nor was an antileukemic effect observed following challenge with leukemia cells (Supplementary Figure 1d) .
Discussion
We have investigated the outcome of early and delayed CTLA-4 blockade after miHC-mismatched BMT. We found that delayed CTLA-4 blockade induces a potent antileukemic effect that is driven by host cells, and that occurs in the context of a severe systemic autoreactive lymphoproliferative condition. This syndrome was mirrored by spontaneous ex vivo proliferation of host lymphoid cells. Proliferation assays using DC, pulsed with hosttype self-peptides and leukemia-derived peptides, proved that the anti-self reactivity and antileukemic reactivity were selectively host-and not donor-derived. Bidirectional host-donor transplantation tolerance was preserved, indicating that, at this 
Proliferative responses of d35 splenocytes against DC pulsed with host salivary gland peptides (sg), BW 5147.3 leukemia cell peptides (bw) or towards nonpulsed DC (np). (mean7s.e., n ¼ 15;
Host-derived antileukemic effect of CTLA-4 blockade S Fevery et al late stage, transplantation tolerance had become insensitive to CTLA-4 blockade. This was distinct from the effect of early CTLA-4 blockade, which led to acute GVHD, indicating that, at this early stage, CTLA-4 is required to downregulate the alloreactivity of host-reactive T cells and to prevent GVHD. 28 The observed CTLA-4 blockade-induced autoimmune condition is reminiscent of the lethal lymphoproliferative disease in CTLA-4 À/À mice or anti-CTLA-4-treated neonatal mice. [13] [14] [15] 43 After irradiation and syngeneic BMT of host-type AKR mice, CTLA-4 blockade gave rise to mild lymphoproliferation only. In addition, it left untransplanted adult host-type AKR mice unaffected, and in neither of both settings did it induce a GVL effect. Thus, CTLA-4 seems to play a pivotal role in regulating anti-self reactivity under conditions of lymphohematopoietic expansion. Furthermore, the severity of the CTLA-4 blockadeinduced syndrome following allogeneic transplants possibly relates to a more inflammatory environment, lowering the threshold for and thus favoring self-reactivity. Donor T cells are generally considered the principal GVL effector cells, 1, 44, 45 and host-type APC cooperate in initiating both GVHD and GVL. 5, [46] [47] [48] However, recent mouse studies have indicated that other host factors, for example T cells, can contribute to antileukemic responses. 49, 50 Also, strong antitumor responses, despite loss of donor chimerism, have been observed after nonmyeloablative HSCT. 51 Our data further support the notion that host T cells may play an effector role in mediating antitumor effects. Autoimmune manifestations following CTLA-4 blockade have been a concern in other experimental studies and clinical treatment protocols. The combination of anti-CTLA-4 mAb with GM-CSF-expressing tumor vaccines against B16-BL6 melanoma in mice resulted in tumor rejection in 80% of the animals, but 56% of them developed depigmentation. 52 In phase I clinical trials, the combination of melanoma vaccines with anti-CTLA-4 mAb induced cancer regression, but with antinuclear Ab and autoimmune manifestations in colon, liver, skin, eye and pituitary glands as side effects. [24] [25] [26] [27] 53 The immunopathogenesis of the observed autoimmune condition is as yet not resolved but the subject of ongoing studies. Our data suggest that mechanisms of self-tolerance and transplant rejection are differentially affected by delayed and early CTLA-4 blockade. We hypothesize that DC contribute to transplantation tolerance by inducing a deletional type of tolerance, insensitive to delayed CTLA-4 blockade. Tolerance induction for organ-specific peptides, however, may depend on their appropriate expression by thymic epithelial cells, which could be sensitive to radiation and CTLA-4 blockade. Although the role of CTLA-4 in thymic clonal deletion is controversial, 13, 14, [54] [55] [56] [57] delayed CTLA-4 blockade in our model was not associated with altered clonal deletion of alloreactive T cells.
CTLA-4 can affect the function of natural regulatory T cells (T reg ), 43, 58, 59 which regulate self-tolerance, and their role in transplantation tolerance, GVHD and tumor immune surveillance is increasingly being recognized. [60] [61] [62] [63] Reports on the function of T reg in CTLA-4 À/À mice are conflicting, 43, 64 and preliminary results in our model indicate that CTLA-4 blockade does not induce T reg -cell defects, but rather induces IL-10 production in T effector cells. Although the latter finding was previously reported in CTLA4
À/À CTLA4-Ig-transgene mice, its significance is as yet not understood. 64 Finally, it is as yet unclear why host and not donor T cells are affected by delayed CTLA-4 blockade. CTLA-4 negatively regulates both naïve and memory CD4 þ T cells, but may regulate only memory CD8 þ T cells. 15, 52, 65, 66 Memory T cells gain easier access to tissue-specific self-antigens, and we are currently investigating if naïve and memory host and donor T cells recover with differential kinetics after BMT.
In summary, CTLA-4 blockade can induce a strong antileukemic effect while leaving donor-host tolerance untouched and avoiding GVHD, a long pursued goal in allogeneic HSCT. However, the antileukemic benefit was offset by autoimmune mortality. Strategies to control autoimmunity while preserving GVL, as recently demonstrated in mouse and patient studies of anti-CTLA-4 therapy for solid tumors, [24] [25] [26] [27] 53, 67, 68 are currently being explored. Our data provide evidence that CTLA-4 blockade represents a potentially valuable target for the design of adjuvant immunotherapy after allogeneic HSCT for leukemia. Host-derived antileukemic effect of CTLA-4 blockade S Fevery et al Meerbeek, 5 Erna Van Dissel 5 and Dr Gert De Hertogh. 5 We thank the staff of the animal facility for providing excellent animal care.
